AURKB is a viable target in SCLC [6], and our mechanistic studies in SCLC cells treated with FOXM1i coupled with global transcriptomic studies, including Gene Set Enrichment analysis revealed that AURKB is one of the top downregulated pathways, which was further validated in our in vitro and in vivo models. Here, AURKB is linked to small cell lung carcinoma.